NEO1 and NEO-EXT Studies: Long-Term Safety of Repeat Avalglucosidase Alfa Dosing for 4.5 Years in Patients With Late-Onset Pompe Disease
Publication
, Conference
Dimachkie, MM; Barohn, RJ; Kishnani, PS; Ladha, S; Mengel, KE; Pena, LDM; Sacconi, S; Van Damme, P; Vissing, J; Haack, K; Hug, C; Johnson, J ...
Published in: NEUROLOGY
April 9, 2019
Duke Scholars
Published In
NEUROLOGY
EISSN
1526-632X
ISSN
0028-3878
Publication Date
April 9, 2019
Volume
92
Issue
15
Location
Philadelphia, PA
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
71st Annual Meeting of the American-Academy-of-Neurology (AAN)
Related Subject Headings
- Neurology & Neurosurgery
- 3209 Neurosciences
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Dimachkie, M. M., Barohn, R. J., Kishnani, P. S., Ladha, S., Mengel, K. E., Pena, L. D. M., … Schoser, B. (2019). NEO1 and NEO-EXT Studies: Long-Term Safety of Repeat Avalglucosidase Alfa Dosing for 4.5 Years in Patients With Late-Onset Pompe Disease. In NEUROLOGY (Vol. 92). Philadelphia, PA: LIPPINCOTT WILLIAMS & WILKINS.
Dimachkie, Mazen M., Richard J. Barohn, Priya S. Kishnani, Shafeeq Ladha, Karl Eugen Mengel, Loren D. M. Pena, Sabrina Sacconi, et al. “NEO1 and NEO-EXT Studies: Long-Term Safety of Repeat Avalglucosidase Alfa Dosing for 4.5 Years in Patients With Late-Onset Pompe Disease.” In NEUROLOGY, Vol. 92. LIPPINCOTT WILLIAMS & WILKINS, 2019.
Dimachkie MM, Barohn RJ, Kishnani PS, Ladha S, Mengel KE, Pena LDM, et al. NEO1 and NEO-EXT Studies: Long-Term Safety of Repeat Avalglucosidase Alfa Dosing for 4.5 Years in Patients With Late-Onset Pompe Disease. In: NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2019.
Dimachkie, Mazen M., et al. “NEO1 and NEO-EXT Studies: Long-Term Safety of Repeat Avalglucosidase Alfa Dosing for 4.5 Years in Patients With Late-Onset Pompe Disease.” NEUROLOGY, vol. 92, no. 15, LIPPINCOTT WILLIAMS & WILKINS, 2019.
Dimachkie MM, Barohn RJ, Kishnani PS, Ladha S, Mengel KE, Pena LDM, Sacconi S, Van Damme P, Vissing J, Haack K, Hug C, Johnson J, Sensinger C, Schoser B. NEO1 and NEO-EXT Studies: Long-Term Safety of Repeat Avalglucosidase Alfa Dosing for 4.5 Years in Patients With Late-Onset Pompe Disease. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2019.
Published In
NEUROLOGY
EISSN
1526-632X
ISSN
0028-3878
Publication Date
April 9, 2019
Volume
92
Issue
15
Location
Philadelphia, PA
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
71st Annual Meeting of the American-Academy-of-Neurology (AAN)
Related Subject Headings
- Neurology & Neurosurgery
- 3209 Neurosciences
- 3202 Clinical sciences